Drugs / LP-10
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03129126 | Oct 2020 → Aug 2023 | hemorrhagic cystitis | Lipella Pharmaceuticals, Inc. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 4
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | Lipella Pharmaceuticals, Inc. | Results Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus lipella.com ↗ |
| 2025-04-23 | Lipella Pharmaceuticals, Inc. | Results Lipella Pharmaceuticals Abstract Accepted for Podium Presentation at the 2025 AAOM/EAOM International Meeting lipella.com ↗
Topline study results demonstrate clinically meaningful improvements in OLP |
| 2025-02-11 | Lipella Pharmaceuticals, Inc. | Results Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in Oral Lichen Planus lipella.com ↗ |
| 2023-01-11 | Lipella Pharmaceuticals, Inc. | Results Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 lipella.com ↗
today announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-09-18 | Lipella Pharmaceuticals, Inc. | Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus lipella.com ↗ |
| 2025-05-15 | Lipella Pharmaceuticals, Inc. | Lipella Pharmaceuticals to Present Phase 2a Data for LP-10 at the 2025 AAOM/EAOM International Meeting lipella.com ↗ |
| 2025-04-23 | Lipella Pharmaceuticals, Inc. | Lipella Pharmaceuticals Abstract Accepted for Podium Presentation at the 2025 AAOM/EAOM International Meeting lipella.com ↗ |
| 2025-02-11 | Lipella Pharmaceuticals, Inc. | Lipella Pharmaceuticals Reports Positive Topline Phase 2a Results for LP-310 in Oral Lichen Planus lipella.com ↗ |
| 2023-01-11 | Lipella Pharmaceuticals, Inc. | Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 lipella.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LP-10 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03129126 ↗ |
| Known as | tacrolimus | “The purpose of this study is to assess the safety and tolerability of three doses of LP-10 (intravesical tacrolimus).” NCT03129126 ↗ |
| Route | Other | “Intravesical tacrolimus” NCT03129126 ↗ |